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Introduction
It	 is	 estimated	 that	 approximately	
30–40%	 of	 patients	 for	 coronary	 artery	
bypass	 graft	 surgery	 (CABG)	 have	
diabetes	 mellitus	 or	 impaired	 glucose	
tolerance.[1,2]	 These	 patients	 present	 higher	
incidence	 of	 morbidity	 and	 mortality	 and	
increased	length	of	hospital	stay.[3,4]
Adequate	 glycemic	 control	 in	
perioperative	 period	 is	 essential	 for	
improving	 the	 outcome	 in	 surgical	
patients,	 especially	 those	 undergoing	
CABG.[5]	 However,	 the	 uncertainty	
still	 remains	 in	 the	 appropriate	 level	 of	
perioperative	 glycemic	 control	 needed	
to	 achieve	 the	 best	 possible	 outcome.	
Some	 researchers	 advocate	 tight	 glycemic	
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Background:	 Diabetes	 is	 not	 uncommon	 in	 patients	 requiring	 cardiac	 surgery.	 These	 patients	
have	 a	 higher	 incidence	 of	 morbidity	 and	 mortality.	 Subsequently,	 diabetes	 represents	 a	 major	
medico‑economic	problem	 in	both	developed	and	developing	 countries.	This	 study	was	designed	 to	
observe	 the	 association	 between	 glycemic	 control	 and	 outcome	 of	 patients	 after	 open	 heart	 surgery	
in	adult	population.	Materials and Methods:	Data	was	collected	retrospectively	 in	all	patients	who	
underwent	open	cardiac	surgery	(coronary	artery	bypass	grafting,	valve,	or	bypass	grafting	with	valve	
surgery)	 and	 survived	 72	 hours	 postoperatively	 and	 had	 diabetes.	 The	 study	 was	 conducted	 from	
January	2015	to	December	2016.	Results:	Of	the	129	patients	included	in	the	study,	male	dominated	
101	 (78.3%).	 Most	 frequent	 surgery	 was	 coronary	 artery	 bypass	 grafting	 (CABG)	 123	 (95.3%),	
CABG	plus	 aortic	valve	 replacement	4	 (3.1%),	 and	CABG	plus	mitral	valve	 replacement	2	 (1.6%).	
Considering	 diabetes,	 only	 3	 (2.3%)	 were	 on	 diet	 control,	 112	 (86.8%)	 on	 oral	 hypoglycemic	
agents	 (OHA),	 whereas	 9	 (7%)	 had	 control	 on	 both	 insulin	 and	 OHA.	 Only	 5	 (3.9%)	 had	
type	 I	 diabetes.	 The	 mean	 fasting	 blood	 sugar	 (FBS)	 was	 154.58	 g/dl,	 and	 the	 mean	 duration	 of	
diabetic	 mellitus	 was	 observed	 12.32	 years.	 Microvascular	 and	 macrovascular	 complications	 were	
26/129	 (20.16%)	 and	 17/129	 (13.17%),	 respectively.	 Total	 75	 (58.1%)	 patients	 did	 not	 require	
insulin	and	54	(41.9%)	were	treated	with	insulin	intraoperatively	to	keep	the	blood	glucose	level	less	
than	 200	 g/dl.	 Cardiac	 arrhythmias	were	 frequent	 in	 the	 insulin	 group	 (P	 <	 0.05),	 which	was	 also	
associated	with	 increased	 stay	 in	 the	 cardiac	 intensive	 care	 unit.	Conclusion:	 Inadequate	 glycemic	
control	 during	 open	 cardiac	 surgery	 can	 possibly	 lead	 to	 increased	 perioperative	 morbidity	 and	
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control	 (blood	 glucose	 80–110	 mg/dl)	 to	
improve	 outcome	 and	 decreased	 wound	
infections.[6,7]	 Whereas	 others	 reported	 no	
improvement	 in	 morbidity	 and	 mortality	
with	 the	 tight	 control	 and	 even	 suggest	
possibilities	 of	 some	 adverse	 effects	 in	
such	patients.[8]
As	 a	 consequence	 of	 these	 conflicting	 data	
and	 some	 recent	 research,[9]	 the	 Institute	
for	 Healthcare	 Improvement	 and	 Society	
of	 thoracic	 surgeons	 guidelines[10‑12]	
recommend	 keeping	 blood	 glucose	 levels	
to	less	than	180	mg/dl	both	intraoperatively	
and	during	the	ICU	stay.
The	 objective	 of	 this	 study	 was	 to	
observe	 the	 association	 between	
perioperative 	 glycemic	 control	 and	 the	
outcome	 of	 patients	 following	 open	 heart	
surgery.This is an open access journal, and articles are 
distributed under the terms of the Creative Commons 
Attribution‑NonCommercial‑ShareAlike 4.0 License, which allows 
others to remix, tweak, and build upon the work non‑commercially, 
as long as appropriate credit is given and the new creations are 
licensed under the identical terms.
For reprints contact: reprints@medknow.com
Siddiqui, et al.: Open heart surgery in diabetic patients
Annals of Cardiac Anaesthesia | Volume 22 | Issue 3 | July‑September 2019 261
Materials and Methods
This	was	a	retrospective	cohort	study	and	was	exempted 		by	
the	 Ethical	 Review	 Committee	 of	 Aga	 Khan	 University	
for	 informed	 consent.	 Patients	 having	 diabetes	 who	 were	
admitted	 for	 open	 heart	 surgery	 in	 the	 last	 2	 years	 from	
January	 2015	 to	December	 2016	with	 survival	 for	 at	 least	
72	h	were	enrolled	in	this	study.
Patients	 with	 diabetes	 mellitus	 either	 on	 diet	 control,	
insulin	 dependent	 or	 noninsulin	 dependent	 before	 open	
heart	 surgery	 (CABG,	 valves	 replacement	 and	 bypass	
grafting	 with	 valve	 surgery)	 were	 included	 in	 the	 study.	
Patients	 with	 nondiabetic,	 poor	 glycemic	 control,	 having	
emergency	 surgery,	 having	 surgery	 with	 off‑pump	
bypass,	 age	 less	 than	 18	 years,	 on	 dialysis,	 and	 having	 a	




numbers	 were	 obtained,	 files	 were	 retrieved	 from	medical	
records,	 and	 data	 were	 collected	 on	 a	 predesigned	 data	
collecting	form	by	one	of	the	investigators.
All	 statistical	 analyses	 was	 performed	 using	 Statistical	
Packages	 for	 Social	 Science	 version	 19	 (SPSS	 Inc.,	
Chicago,	 IL,	 USA).	 Mean	 and	 standard	 deviation	 were	
computed	 for	 quantitative	 observation	 and	 analyzed	
by	 independent	 sample	 t‑test	 whereas	 proportion	 and	




A	total	of	129	patients	were	observed	 in	 the	study	over	 the	
period	of	2	years.	Demographic	 features,	surgical	variables,	
and	 disease	 measures	 for	 all	 129	 patients	 are	 outlined	 in	
Table	 1.	 There	 were	 101	 (78.3%)	 males	 and	 28	 (21.7%)	
females.	 Most	 frequent	 surgery	 was	 CABG	 alone	
123	 (95.3%),	 CABG	 plus	 aortic	 valve	 replacement	 (AVR)	
4	(3.1%),	and	CABG	plus	mitral	valve	replacement	(MVR)	
2	 (1.6%).	 The	 control	 of	 diabetes	 mellitus	 (on	 diet	
control,	 insulin	 alone,	 or	 combination	 of	 insulin	 with	 oral	
hypoglycemic	 agents	 [OHA])	 was	 also	 observed.	 Only	
3	(2.3%)	had	diet	control	diabetes,	112	(86.8%)	had	diabetes	
control	with	 oral	 hypoglycemic	 agents	 (OHA),	 9	 (7%)	 had	
diabetes	 control	 through	 insulin	 with	 OHA,	 and	 5	 (3.9%)	
had	controlled	it	with	insulin	alone.	The	mean	fasting	blood	
sugar	(FBS)	was	154.58	±	55.56	g/dl	and	the	mean	duration	
of	 diabetic	 mellitus	 was	 12.32	 ±	 5.49	 years.	 Recurrent	
hypoglycemia	 was	 observed	 only	 in	 one	 female	 patient	
preoperatively	who	 had	 diet	 control	 diabetes.	 No	 intra	 and	
postoperative	complications	were	found	in	that	patient.
Further,	 prior	 history	 of	 both	 macro	 and	 microvascular	
complications	 related	 to	 DM	 were	 also	 observed.	
Microvascular	 complications	 were	 detected	 in	
26/129	 (20.16%)	 and	 macrovascular	 complications	 were	
detected	 in	 17/129	 (13.17%).	Microvascular	 complications	
were	 categorized	 as	 retinopathy,	 neuropathy,	 and	
nephropathy,	 whereas	 macrovascular	 complications	 were	
categorized	 as	 prior	 myocardial	 infarction	 (MI),	 prior	
congestive	 heart	 failure	 (CHF),	 and	 peripheral	 vascular	
disease	(PVD)	[Table	2].
Assessments	were	done	related	to	the	methods	to	control	
diabetes	 during	 the	 intraoperative	 phase	 and	 blood	
glucose	 levels,	 both	 intra	 and	 postoperatively	 [Table	 3].	
It	 was	 found	 that	 75	 (58.1%)	 patients	 did	 not	 require	
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Discussion
Perioperative	 blood	 glucose	 control	 and	 administration	 of	
insulin	 during	 open	 heart	 surgery	 in	 diabetic	 patients	 is	
expected	 to	 have	 beneficial	 effects	 on	 patients’	 outcome.	
Administration	 of	 insulin	 will	 increase	 glucose	 uptake	 by	
myocytes,	 promoting	 glycogenesis,	 and	 reducing	 free	 fatty	
acids,	while	 protecting	 heart	 against	 ischemia	 provided	 by	
cardiopulmonary	 bypass.[13]	 Furthermore,	 hyperglycemia	
has	 a	 pro‑inflammatory	 effect	 that	 may	 contribute	 to	
postoperative	capillary	leak	syndrome,	platelet	dysfunction,	
and	 altered	 immune	 response	 that	 could	 be	 avoided	 by	
blood	glucose	control.[14]
By	 revision	 of	 studies	 conducted	 on	 the	 effect	 of	 tight	
glycemic	 control	 of	 diabetic	 patients	 on	 patients’	 outcome	
after	 CABG	 surgery,	 there	 was	 no	 fixed	 blood	 glucose	
range	 taken	 as	 a	 single	 reference	 in	 these	 studies.	 The	
definition	 of	 tight	 glycemic	 control	 was	 different	 and	 the	
method	 by	 which	 one	 can	 achieve	 it	 was	 also	 varied.	 To	
date,	 it	 remains	 unclear	 how	 tight	 the	 glycemic	 control	
should	 be.	 For	 safety,	 in	 our	 study,	 the	 recommendations	
of	 American	 Association	 of	 Clinical	 Endocrinologists	
and	 American	 Diabetes	 Association	 (ADA/AACE)	 were	
followed	 to	 define	 tight	 glycemic	 control	 to	 be	 between	
110	 and	 149	 mg/dl	 and	 moderate	 glycemic	 control	 to	 be	
between	150	and	180	mg/dl.[12]
In	2009,	normoglycemia	in	Intensive	Care	Evaluation‑Survival	
Using	 Glucose	Algorithm	 Regulation	 (NICE‑SUGAR)	 trial	
made	much	 change	 in	 concept	 of	 tight	 glycemic	 control	 as	
they	 found	 that	 intensive	 glucose	 control	 (81–108	 mg/dl)	
actually	 increased	 90‑day	 mortality	 with	 more	 episodes	 of	
hypoglycemia	 recommending	 more	 liberal	 control	 of	 blood	
glucose	level.[15]
Numerous	 studies	 have	 now	 shown	 that	 patients	
with	 acute	 coronary	 syndromes	 (ACS)	 who	 present	
with	 hyperglycemia	 are	 at	 a	 higher	 risk	 of	 death	
and	 in‑hospital	 complications.[16‑18]	 Capes	 and	
co‑workers[19]	 in	 meta‑analysis	 of	 15	 studies	 showed	 that	
the	 risk	 of	 in‑hospital	 death	 in	 nondiabetic	 patients	 with	
ACS	 and	 the	 admission	 glucose	 >110	mg/dl	was	 3.9	 times	
greater	than	in	patients	who	were	normoglycemic.
Desai	et al.[20]	 found	 in	a	 study	on	 isolated	CABG	patients	
that	 liberal	 blood	 glucose	 control	 between	 121	 and	
180	mg/dl	have	better	outcome	in	relation	to	blood	glucose	
control	 and	 target	 range	 needed	 and	 similar	 outcome	 to	
tight	glycemic	control	regarding	morbidity	and	mortality.
Girish	 et al.[21]	 also	 supported	 in	 their	 review	 that	 it	
is	 sensible	 to	 maintain	 blood	 sugar	 level	 between	 a	
safe	 intermediate	 range	 of	 140–180	 mg/dl	 or	 better	
still	<150	mg/dl	keeping	 in	view	 the	potentially	dangerous	
consequences	of	hypoglycemia	and	hyperglycemia.
The	 relationship	 between	 tight	 glycemic	 control	 and	
decreased	 surgical	 wound	 infection	 was	 addressed	 first	






















Table 4: Intraoperative control of blood sugar and 








Renal	failure 20	(26.7%) 25	(46.3%) 0.021
Cardiac	arrhythmias 5	(6.7%) 12	(22.2%) 0.01*
Myocardial	infarction 0 0 NA
Deep	sternal	infection 2	(2.7%) 0	(0%) 0.509
Multisystem	failure 2	(2.7%) 1	(1.9%) 0.762
ventilator	support	>24	hours 5	(6.7%) 12	(22.2%) 0.016









insulin	 intraoperatively,	 and	 54	 (41.9%)	 patients	 were	
managed 	 by	 bolus	 insulin	 	 during	 the	 intraoperative	
phase;	 the	 frequency	 of	 bolus	 dose	 was	 also	monitored.	
The	average	dose	of	insulin	was	13.1	IU.	In	patients	who	
received	 insulin	 intra‑operatively,	 average	 blood	glucose	
level	 was	 243.6	 g/dl.	 The	 threshold	 to	 use	 insulin	
bolus	 was	 blood	 sugar	 more	 than	 180	 g/dl.	 In	 addition,	
102	 patients	 needed	 insulin	 boluses	 on	 day	 one,	 91	 on	
day	two,	and	81	on	day	three	after	 the	surgery.
Patients	 were	 followed	 postoperatively	 despite	 patients’	
glucose	 managed	 with	 or	 without	 insulin	 and	 monitored	
for	 any	 postoperative	 complication.	 Cardiac	 arrhythmias,	
renal	 failure,	 ventilator	 support	 >24	 hours,	 and	 length	 of	
stay	>3	were	statistically	significant	among	patients	having	
insulin	for	 targeted	glycemic	control	 (<200	g/dl)	 in	cardiac	
intensive	care	unit	(CICU)	[Table	4].
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in	 1991	 when	 the	 American	 College	 of	 Cardiology	 and	
American	 Heart	 Association	 noted	 increased	 incidence	 of	
wound	infection	in	diabetic	patients.[22]
A	 cohort	 study	 by	 Estrada	 et al.[23]	 of	 1574	 patients	 who	
had	 undergone	 coronary	 artery	 bypass	 grafting	 assessed	
for	 30	 days	 for	mortality,	 infection	 rates	 (sternum,	 harvest	
site,	 sepsis,	 pneumonia,	 urinary	 tract),	 and	 the	 utilization	
of	 resources	 found	 no	 statistical	 significant	 relationship	
between	 surgical	 site	 infection	 and	 blood	 glucose	 level	
between	diabetic	and	nondiabetic	groups.
Arrhythmias	 following	 cardiac	 surgery	 are	 common	
affecting	 up	 to	 20–30%	 of	 patients.[24]	 The	 mechanisms	
by	 which	 atrial	 fibrillation	 can	 occur	 after	 cardiac	
surgery	 is	 unclear,	 but	 certain	 theories	 such	 as	 cooling	 of	
atrium,	 increased	 sympathetic	 activity,	 and	 withdrawal	 of	
preoperative	 B‑blockers	 are	 acknowledged	 on	 animal	 and	
human	 trials.[25,26]	All	 the	 previous	 factors	 could	 contribute	
to	change	in	refractory	period	in	the	atrium	predisposing	to	
atrial	 fibrillation.[27]	 In	 our	 study,	 a	 significant	 reduction	 in	
arrhythmias	was	 found	 in	group	which	was	not	on	 insulin.	
This	 is	a	unique	finding	in	this	study	but	other	studies	also	
support	 tight	 glycemic	 with	 better	 arrhythmias	 control	 in	
this	regard.[6,28]
Length	 of	 CICU	 stay	 was	 also	 relatively	 high	 in	 patients	
who	 received	 insulin	 to	 manage	 glycemic	 control	
intraoperatively	 compared	 with	 those	 who	 did	 not	 receive	
insulin	 for	 glycemic	 control.	 These	 findings	 were	 also	
contradictory	 to	 other	 studies	 which	 showed	 a	 significant	
reduction	 in	 the	 amount	 of	 time	 spent	 on	 ventilation	 for	
patients	 who	 had	 tight	 glycemic	 control.	 However,	 there	
was	 also	 significant	 heterogeneity	 in	 the	 data.[6,29]	 On	 the	
contrary,	 another	 study	 stated	 that	 hypoglycemia	 with	
thorough	 insulin	 therapy	 is	 independently	 associated	 with	
increased	 risk	 for	 respiratory	 complications	 and	 prolonged	
hospital	and	 intensive	care	unit	 length	of	 stay	after	cardiac	
surgery.[30]
Based	 on	 recent	 information,	 the	 new	 Society	 of	Thoracic	
Surgeons	 guidelines	 and	 the	 American	 Association	
of	 Clinical	 Endocrinologists	 and	 American	 Diabetes	
Association	 (AACE/ADA)	 consensus	 statement	 seem	
appropriate	 and	 allay	 the	 concern	 for	 hypoglycemia	 with	
the	new	recommended	range	of	<180	and	140–180	mg/dl.[31]	
More	 studies	 analyzing	 blood	 glucose	 target	 ranges	 are	
required	 to	 further	 recommend	 an	 intensive	 blood	 glucose	
goal	 range	 of	 80–110	 mg/dL,	 especially	 in	 the	 cardiac	
surgery	 population.	 Even	 throughout	 the	 Van	 Den	 Berghe	
trials[32,33]	 the	 average	 blood	 sugar	 of	 patients	 in	 the	
intensive	control	arm	was	approximately	140	mg/dL.	Thus,	
aiming	 for	 blood	 glucose	 levels	 around	140	mg/dl	 appears	
reasonable.	Mortality	 and	morbidity	 benefits	 are	 seen	with	
overall	control	of	hyperglycemia;	however,	 the	exact	 range	
is	still	not	clearly	defined,	as	previously	thought.	Additional	
comparisons	 of	 specific	 glucose	 ranges	 would	 allow	 for	
a	 clearer	 definition	 of	 recommended	 blood	 glucose	 goals	
in	 postoperative	 cardiac	 patients,	 resulting	 in	 the	 best	
outcomes	 and	 least	 incidence	 of	 hypoglycemia.	 Therefore,	
more	 studies	 are	 recommended	 with	 greater	 sample	 size	




Hypo	 or	 hyperglycemia	 during	 open	 cardiac	 surgery	 can	
possibly	 lead	 to	 increased	 perioperative	 morbidity	 and	
mortality	 and	 can	 be	 associated	 with	 decreased	 long‑term	
survival	 and	 recurring	 ischemic	 events.	 Therefore,	 aiming	
for	 blood	 glucose	 levels	 around	 140	 mg/dl	 appears	
reasonable;	 however,	 the	 exact	 range	 is	 still	 not	 clearly	
defined.	 Further	 studies	 are	 required	 to	 define	 specific	
glucose	 ranges	 for	 a	 clearer	 definition	 of	 recommended	
blood	 glucose	 goals	 in	 postoperative	 cardiac	 patients	 for	
the	best	outcomes	in	patients	with	diabetes	mellitus.
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